MYC and neoplasm: Indeed, we found that targeting PFKP with siRNA or shRNA in combination with a c-Myc inhibitor had a potent anti-tumor effect in three preclinical tumor models, including the LIU-LSC-1 CDX, HNSCC PDO, and HNSCC PDX models, respectively.